| P2093 | author name string | Paul Hahn | |
| | Glenn Yiu | |
| | Bozho Todorich | |
| P2860 | cites work | Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis | Q24313372 |
| | Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1 | Q24316075 |
| | Treatment of leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results of a phase I trial | Q24608049 |
| | Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity | Q24609568 |
| | Ranibizumab and bevacizumab for neovascular age-related macular degeneration | Q24616209 |
| | Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results | Q24633874 |
| | Safety and efficacy of gene transfer for Leber's congenital amaurosis | Q24634724 |
| | Human RPE65 gene therapy for Leber congenital amaurosis: persistence of early visual improvements and safety at 1 year | Q24634801 |
| | The time course changes of choroidal neovascularization in angioid streaks. | Q50488474 |
| | EVEREST study: efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy. | Q50500639 |
| | Intravitreal bevacizumab for exudative age-related macular degeneration after multiple treatments. | Q50706391 |
| | Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. | Q52886344 |
| | Complement factor H variant Y402H is a major risk determinant for geographic atrophy and choroidal neovascularization in smokers and nonsmokers. | Q53555067 |
| | Astrocytes modulate retinal vasculogenesis: effects on endothelial cell differentiation. | Q55480472 |
| | Photodynamic Therapy of Subfoveal Choroidal Neovascularization in Age-related Macular Degeneration With Verteporfin | Q56812915 |
| | Astrocytes induce blood–brain barrier properties in endothelial cells | Q57318253 |
| | Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors | Q24676378 |
| | Vascular endothelial growth factor B (VEGF-B) binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cells | Q24679724 |
| | Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen | Q27620162 |
| | VEGF-D promotes the metastatic spread of tumor cells via the lymphatics | Q28200072 |
| | Engineered antibodies | Q28201899 |
| | Laser photocoagulation for choroidal neovascular membrane associated with optic disc drusen | Q28252627 |
| | High-affinity binders selected from designed ankyrin repeat protein libraries | Q28257550 |
| | Primary intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration: results of the Pan-American Collaborative Retina Study Group at 12 months follow-up | Q28295656 |
| | Preretinal neovascularisation associated with choroidal melanoma | Q28362436 |
| | Dominant-negative and targeted null mutations in the endothelial receptor tyrosine kinase, tek, reveal a critical role in vasculogenesis of the embryo | Q28586040 |
| | Mechanisms of angiogenesis | Q29547485 |
| | Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele | Q29547733 |
| | Mechanisms of angiogenesis and arteriogenesis | Q29617257 |
| | Ranibizumab for neovascular age-related macular degeneration | Q29617549 |
| | Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer | Q29622818 |
| | The mouse retina as an angiogenesis model | Q30495106 |
| | Presumed ocular histoplasmosis syndrome: update on epidemiology, pathogenesis, and photodynamic, antiangiogenic, and surgical therapies | Q30773488 |
| | Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. | Q30824036 |
| | Intravitreal injection of bevacizumab (avastin) for treatment of stage 3 retinopathy of prematurity in zone I or posterior zone II. | Q30844301 |
| | Human retinal molecular weight exclusion limit and estimate of species variation | Q30919500 |
| | Designing repeat proteins: well-expressed, soluble and stable proteins from combinatorial libraries of consensus ankyrin repeat proteins. | Q30979207 |
| | Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin. 1-year results of a randomized clinical trial--VIP report no. 1. | Q30988238 |
| | Maximum tolerated dose of a humanized anti-vascular endothelial growth factor antibody fragment for treating neovascular age-related macular degeneration. | Q31172091 |
| | Use of intravitreal bevacizumab as a preoperative adjunct for tractional retinal detachment repair in severe proliferative diabetic retinopathy | Q33249402 |
| | Angiogenic and antiangiogenic factors in proliferative diabetic retinopathy. | Q33316526 |
| | Off-label use of intravitreal bevacizumab (Avastin) for salvage treatment in progressive threshold retinopathy of prematurity. | Q33322288 |
| | Acute contraction of the proliferative membrane after an intravitreal injection of bevacizumab for advanced retinopathy of prematurity | Q33322542 |
| | Endogenous VEGF is required for visual function: evidence for a survival role on müller cells and photoreceptors | Q33382103 |
| | The role of PGE2 receptor EP4 in pathologic ocular angiogenesis | Q33459697 |
| | Clinical factors related to recurrence of anterior segment neovascularization after treatment including intravitreal bevacizumab | Q33551829 |
| | Effects of intravitreal bevacizumab and laser in retinopathy of prematurity therapy on the development of peripheral retinal vessels | Q33555925 |
| | Reduced Choroidal Neovascular Membrane Formation in Cyclooxygenase-2 Null Mice | Q33706172 |
| | Inhibition of choroidal neovascularization in a nonhuman primate model by intravitreal administration of an AAV2 vector expressing a novel anti-VEGF molecule | Q33729384 |
| | Digoxin inhibits retinal ischemia-induced HIF-1alpha expression and ocular neovascularization | Q33868764 |
| | Retinal and choroidal neovascularization | Q33980639 |
| | Polarized vascular endothelial growth factor secretion by human retinal pigment epithelium and localization of vascular endothelial growth factor receptors on the inner choriocapillaris. Evidence for a trophic paracrine relation | Q40937602 |
| | Regulation of vascular endothelial growth factor expression by insulin-like growth factor I. | Q41089071 |
| | Differential transcriptional regulation of the two vascular endothelial growth factor receptor genes. Flt-1, but not Flk-1/KDR, is up-regulated by hypoxia. | Q41091104 |
| | Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab | Q42139247 |
| | Age-related macular degeneration histopathologic studies. The 1992 Lorenz E. Zimmerman Lecture | Q42483851 |
| | Vitrectomy after intravitreal bevacizumab (Avastin) for retinal detachment in retinopathy of prematurity | Q43132463 |
| | Radiation retinopathy--clinical, histopathological, ultrastructural and experimental correlations | Q43634046 |
| | Treatment of idiopathic subfoveal choroidal neovascular lesions using photodynamic therapy with verteporfin | Q44049073 |
| | Macrophages related to Bruch's membrane in age-related macular degeneration | Q44289922 |
| | Chapter 6. Ocular models of angiogenesis | Q44390529 |
| | Novel anti-VEGF chimeric molecules delivered by AAV vectors for inhibition of retinal neovascularization. | Q44953303 |
| | Signaling vascular morphogenesis and maintenance | Q45058276 |
| | Treatment of diabetic macular edema with a designed ankyrin repeat protein that binds vascular endothelial growth factor: a phase I/II study | Q45148015 |
| | Pegaptanib for neovascular age-related macular degeneration | Q45206481 |
| | Intravitreal triamcinolone acetonide compared with bevacizumab for the treatment of patients with macular edema secondary to central retinal vein occlusion | Q45341379 |
| | Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment. | Q45959509 |
| | A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study | Q46045838 |
| | Intraoperative bleeding during vitrectomy for diabetic tractional retinal detachment with versus without preoperative intravitreal bevacizumab (IBeTra study). | Q46125936 |
| | Is there tachyphylaxis to intravitreal anti-vascular endothelial growth factor pharmacotherapy in age-related macular degeneration? | Q46310363 |
| | Expression of cyclooxygenase-2 in choroidal neovascular membranes from age-related macular degeneration patients | Q46338018 |
| | An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration | Q46469410 |
| | Epimacular brachytherapy for neovascular age-related macular degeneration (CABERNET): fluorescein angiography and optical coherence tomography | Q46481610 |
| | Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy | Q46493637 |
| | Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study | Q46528410 |
| | Intravitreal bevacizumab to treat iris neovascularization and neovascular glaucoma secondary to ischemic retinal diseases in 41 consecutive cases. | Q46623669 |
| | Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration (FOCUS): year 2 results | Q46717705 |
| | Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy | Q46927800 |
| | Vascular endothelial growth factor in aqueous humor before and after intravitreal injection of bevacizumab in eyes with diabetic retinopathy | Q46960492 |
| | Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: a short-term study | Q46969343 |
| | Ranibizumab versus Bevacizumab for Neovascular Age-related Macular Degeneration: Results from the GEFAL Noninferiority Randomized Trial | Q47857376 |
| | Ranibizumab for choroidal neovascularization associated with adult-onset foveomacular vitelliform dystrophy: one-year results. | Q50484068 |
| | Bevacizumab-induced tumor vessel remodeling in rhabdomyosarcoma xenografts increases the effectiveness of adjuvant ionizing radiation | Q33995820 |
| | Vasculogenesis and angiogenesis as mechanisms of vascular network formation, growth and remodeling | Q34178814 |
| | Choroidal neovascularization in pathological myopia | Q34262513 |
| | Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders | Q34292807 |
| | Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy | Q34324536 |
| | VEGFR-1 and VEGFR-2: two non-identical twins with a unique physiognomy | Q34333828 |
| | Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate | Q34369354 |
| | Vascular endothelial growth factor is sufficient to produce iris neovascularization and neovascular glaucoma in a nonhuman primate | Q34387729 |
| | Intravitreous injections of vascular endothelial growth factor produce retinal ischemia and microangiopathy in an adult primate | Q34409210 |
| | Highly potent VEGF-A-antagonistic DARPins as anti-angiogenic agents for topical and intravitreal applications | Q34415658 |
| | Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage | Q34498424 |
| | Rapid improvement of rubeosis iridis from a single bevacizumab (Avastin) injection | Q34498429 |
| | Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease | Q34499843 |
| | Clinical and differential utility of VEGF inhibitors in wet age-related macular degeneration: focus on aflibercept | Q34642583 |
| | Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration | Q34650239 |
| | Ranibizumab versus verteporfin for neovascular age-related macular degeneration. | Q34652928 |
| | Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization | Q34749337 |
| | Treatment of subfoveal choroidal neovascularization associated with multifocal choroiditis and panuveitis with photodynamic therapy | Q35004137 |
| | Animal models of oxygen-induced retinopathy | Q35109399 |
| | A new model of experimental choroidal neovascularization in the rat. | Q35125744 |
| | A model of subretinal neovascularization in the pigmented rat. | Q35135509 |
| | Cellular mechanisms in retinal vascular development | Q35174073 |
| | Lasting controversy on ranibizumab and bevacizumab | Q35641933 |
| | An outbreak of streptococcus endophthalmitis after intravitreal injection of bevacizumab | Q35697390 |
| | Risks of intravitreous injection: a comprehensive review | Q35922099 |
| | Retinal angiogenesis in development and disease | Q36342347 |
| | Glaucoma following retinal detachment operations | Q36456275 |
| | Current status of angiogenesis inhibitors combined with radiation therapy | Q36483330 |
| | Nonsteroidal anti-inflammatory drugs for retinal disease | Q36567310 |
| | Subretinal neovascularization. Natural history of an experimental model | Q36590902 |
| | Antivascular endothelial growth factor agents and their development: therapeutic implications in ocular diseases. | Q36608661 |
| | Intravitreal injection of bevacizumab (Avastin) as adjunctive treatment of proliferative diabetic retinopathy | Q36608675 |
| | Combined vascular endothelial growth factor-targeted therapy and radiotherapy for rectal cancer: theory and clinical practice | Q36673500 |
| | Anti-VEGF aptamer (pegaptanib) therapy for ocular vascular diseases | Q36673663 |
| | Review of the pericyte during angiogenesis and its role in cancer and diabetic retinopathy | Q36680668 |
| | VEGF-targeted cancer therapy strategies: current progress, hurdles and future prospects | Q36803200 |
| | Nuclease-resistant nucleic acid ligands to vascular permeability factor/vascular endothelial growth factor | Q36893265 |
| | Pazopanib, a potent orally administered small-molecule multitargeted tyrosine kinase inhibitor for renal cell carcinoma | Q37071204 |
| | Quantitative subanalysis of optical coherence tomography after treatment with ranibizumab for neovascular age-related macular degeneration. | Q37169291 |
| | Levels of vascular endothelial growth factor are elevated in the vitreous of patients with subretinal neovascularisation | Q37319826 |
| | A systematic analysis of the off-label use of bevacizumab for severe retinopathy of prematurity | Q37574523 |
| | Oligodeoxynucleotides inhibit retinal neovascularization in a murine model of proliferative retinopathy | Q37607034 |
| | Therapeutic antibodies in ophthalmology: old is new again | Q37848065 |
| | Avastin doesn't blind people, people blind people | Q37977621 |
| | Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial | Q38009430 |
| | Epimacular brachytherapy for neovascular age-related macular degeneration: a randomized, controlled trial (CABERNET). | Q38061782 |
| | Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab. | Q38109282 |
| | Topical nonsteroidal anti-inflammatory drugs for macular edema. | Q38162433 |
| | 2'-Fluoropyrimidine RNA-based aptamers to the 165-amino acid form of vascular endothelial growth factor (VEGF165). Inhibition of receptor binding and VEGF-induced vascular permeability through interactions requiring the exon 7-encoded domain | Q38335060 |
| | Initial exploration of oral pazopanib in healthy participants and patients with age-related macular degeneration. | Q38443158 |
| | Honokiol inhibits pathological retinal neovascularization in oxygen-induced retinopathy mouse model | Q39114467 |
| | A Phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration | Q39959029 |
| | Ocular neovascularization with retinal vascular occlusion. II. Occurrence in central and branch retinal artery occlusion | Q40104796 |
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | angiogenesis | Q539568 |
| P304 | page(s) | 375-391 | |
| P577 | publication date | 2014-03-03 | |
| P1433 | published in | Expert Review of Clinical Pharmacology | Q15793519 |
| P1476 | title | Current and investigational pharmacotherapeutic approaches for modulating retinal angiogenesis | |
| P478 | volume | 7 | |